COMMUNIQUÉS West-GlobeNewswire
-
Sharecare launches AskMD nationwide to turn any health question into a personalized plan
06/08/2026 -
Silo Pharma Subsidiary QwikAgents Collaborates with Amazon Web Services Premier Tier Partner Caylent to Advance Enterprise AI Platform
06/08/2026 -
Milestone Scientific Schedules Second Quarter 2026 Financial Results Conference Call
06/08/2026 -
Outlook Therapeutics to Report Third Quarter Fiscal Year 2026 Financial Results and Host a Corporate Update Conference Call and Webcast on August 14, 2026
06/08/2026 -
SeaStar Medical to Report Second Quarter Financial Results on August 12, 2026
06/08/2026 -
Celcuity Schedules Release of Second Quarter 2026 Financial Results and Webcast/Conference Call
06/08/2026 -
Vistagen Announces Topline Results for Repeat Dose Study of Fasedienol for Acute Treatment of Social Anxiety Disorder
06/08/2026 -
Propanc Biopharma Announces Positive Preclinical and Early Translational Data for PRP Showing >90% Tumor Growth Inhibition and Significant Survival Benefit in Pancreatic Ductal Adenocarcinoma Models
06/08/2026 -
RenovoRx Announces First Commercial Clinical Use of RenovoCath® in Sarcoma Patient Treatment, Marking Expansion of Targeted Drug-Delivery Device to Other Solid Tumors
06/08/2026 -
iSpecimen Inc. Announces Pricing of $5 Million Public Offering of Common Stock and Pre-Funded Warrants
06/08/2026 -
Onconetix Acquisition Target Realbotix Secures Agreement for Humanoid Robot Appearance on Emmy Award-Winning Streaming Series
06/08/2026 -
SRX Global to Host Fiscal Third Quarter 2026 Conference Call on August 13 at 4:30 p.m. ET
06/08/2026 -
Actimed Therapeutics Reacquires Global Rights to S-oxprenolol, Broadening Pipeline Opportunity
06/08/2026 -
IBA Notice of Half Year 2026 Results and Conference Call
06/08/2026 -
IBA : Publication des résultats du premier semestre 2026 et conférence web
06/08/2026 -
Vivoryon Therapeutics N.V. Reports H1 2026 Financial Results and Provides Business Update
06/08/2026 -
Braveheart Bio Announces Pricing of Upsized Initial Public Offering
06/08/2026 -
ARCPOINT ANNOUNCES FAILURE-TO-FILE CEASE TRADE ORDER
06/08/2026 -
Leads Biolabs’ Opamtistomig (PD-L1/4-1BB Bispecific Antibody) Advances to Expansion Phase in First-Line Hepatocellular Carcinoma Following Positive Efficacy Signals
06/08/2026
Pages